1. In Vivo

Merck & Co, Indian Firms On Tackling Supply Chain Risks And A Hijack

Visibility And Digitization Are Key

 
• By Anju Ghangurde

Merck & Co. executive outlines how the company could sustain a “compliant supply performance” amid the pandemic, while senior officials from Sun Pharma, Cipla, Zydus Cadila and Biocon shared insights on coping with supply chain turbulence and moving away from over-dependence on China for starting materials.

Shipping & Map image

Senior executives from Merck & Co., Inc. and several leading Indian pharma firms have shared insights around how they built supply chain resilience against the backdrop of the general turmoil during the early days of COVID-19. The experiences were also dotted with interesting real world vignettes, including the hijack of a pharma cargo truck in India.

Addressing the recently concluded BioAsia 2021 virtual event, Sanat Chattopadhyay, executive vice-president and president, Merck Manufacturing Division, noted the pandemic had unleashed a “tsunami” of changes, causing an inflection point...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By Jo Shorthouse

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By Jo Shorthouse

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By David Wild

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.